Amikacin Treatment
Conditions
Keywords
Amikacin, intensive care, renal replacement therapy, prescription strategy,, monitoring strategy
Brief summary
Amikacin is the aminoglycoside of choice for treatment of severe infections in intensive care. An achievement of its objectives in pharmacokinetics and pharmacodynamics is difficult in intensive care patients because of modification of their volume of distribution and renal clearance. Acute renal failure requiring renal replacement therapy is frequent in intensive care. Extrarenal purification modalities (continuous versus intermittent, type of dialysis membrane), which can influence amikacin clearance, are multiple and teams dependent. Guidelines of good practice for Amikacin in intensive care patients do not exist.
Detailed description
The aim of this study is to describe strategies of prescription and monitoring of Amikacin in intensive care patients on renal replacement therapy.
Interventions
OTHERData record
Data record
Sponsors
CHU de Reims
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
: * patients in intensive care * patients on extrarenal replacement * patients with Amikacin treatment * patients accepting to participate in the study
Exclusion criteria
: * patients less than 18 years old * pregnant women * patients with Amikacin treatment in the previous 7 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of maximum concentration observed | Day 0 | Monitoring of Amikacin treatment using measurement of maximum concentration observed performed or not |
Countries
France
Outcome results
None listed